NCT07194135

Intra-articular Tenoxicam Versus Triamcinolone Acetonide in Knee Osteoarthritis Management

Completed NA Last updated 26 September 2025

What this trial tests

NA trial testing Tenoxicam in Osteoarthritis, Knee in 100 participants. Completed in 30 April 2025.

Timeline

3 November 2024

Primary endpoint
30 April 2025

30 April 2025

Quick facts

Lead sponsor	Benha University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	3 November 2024
Primary completion	30 April 2025
Estimated completion	30 April 2025
Sites	1 location across Egypt

Drugs / interventions tested

• Tenoxicam — full drug profile →
• Triamcinolone Acetonide — full drug profile →

Conditions studied

• Osteoarthritis, Knee — all drugs for Osteoarthritis, Knee →

Sponsor

Benha University

Who can join

Adults 45 to 75, any sex, with Osteoarthritis, Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Knee osteoarthritis is a very common joint condition that leads to pain, stiffness, and difficulty with daily activities, particularly in middle-aged and older adults. Many patients do not get adequate relief from oral pain medications, non-steroidal anti-inflammatory drugs, or physical therapy. Because of this, injections directly into the knee joint are often used.

Corticosteroid medicines, such as triamcinolone acetonide, are among the most frequently used intra-articular injections. They provide strong and rapid anti-inflammatory effects, but their benefits often wear off after only a few weeks. In addition, corticosteroids may cause unwanted systemic effects such as temporary increases in blood sugar, which can be especially concerning for patients with diabetes.

Non-steroidal anti-inflammatory drugs are another group of medicines that can relieve pain and inflammation. Tenoxicam is a long-acting medicine from this group. When given directly into the knee joint, tenoxicam may provide local pain relief for a longer duration, while reducing the amount of drug that circulates in the body. This may lower the risk of side effects compared with oral treatment or repeated corticosteroid injections.

This clinical study was designed to compare the effects of a single intra-articular injection of tenoxicam with a single intra-articular injection of triamcinolone acetonide in patients who have symptomatic knee osteoarthritis. The primary aim was to determine which treatment provides better improvement in knee pain, measured using a visual analog scale. Secondary aims included evaluating knee function using the Western Ontario and McMaster Universities Osteoarthritis Index, monitoring blood sugar control using glycated hemoglobin testing, and assessing the safety of each treatment by recording any local or general adverse events.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Nanocomposite hydrogels: benefits and attributes for osteoarthritis therapy.
   He J, Chen Y, Zhu H, Hunzla S, et al · · 2026 · PMID 41904460 · DOI 10.1186/s12967-026-08054-9